This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel + carboplatin ( nab-PC ) vs solvent-based paclitaxel + carboplatin ( sb-PC ) as first-line therapy in advanced non-small-cell lung cancer ( NSCLC ) in older patients .